

Table SI. Baseline characteristics of the study population

	Reference ^a (n = 23,162)	Cases ^b (n = 6244)
Age, years, mean (SD)	53.7 (16.9)	54.4 (17.2)
Women, n (%)	13,526 (58.4)	3617 (57.9)
Men, n (%)	9,636 (41.6)	2627 (42.1)
Socio-economic status, mean (SD)	2.0 (1.4)	1.7 (1.4)
Comorbidity, n (%)		
Cardiac dysrhythmias	374 (1.6)	180 (3.0)
COPD	211 (0.9)	130 (2.2)
Diabetes mellitus	282 (1.3)	155 (2.6)
Heart failure	233 (1.0)	115 (1.8)
Hypertension	3,013 (13.0)	1047 (16.8)
Ischaemic heart disease	484 (2.1)	251 (4.0)
Renal disease	70 (0.3)	50 (0.8)
Venous thromboembolism	209 (0.9)	105 (1.7)
Medications, n (%)		
Azathioprine	53 (0.2)	24 (0.4)
Biological drugs	152 (0.7)	61 (1.0)
Cyclosporine	45 (0.2)	25 (0.4)
Glucose-lowering drugs	1,009 (4.4)	393 (6.3)
Methotrexate	805 (3.5)	339 (5.4)
Loop diuretics	1,007 (4.4)	511 (8.2)
Platelet inhibitors	1,940 (8.4)	732 (11.7)
Statins	1,971 (8.5)	616 (9.9)
Systemic glucocorticoids	866 (3.7)	463 (7.4)
Vitamin K antagonists	47 (0.2)	23 (0.4)

^aPsoriasis, never depression. ^bPsoriasis with incident depression.

SD: standard derivation; COPD: chronic obstructive pulmonary disease.